GlassScriptPhysician profile
Marc L Concepcion
NPI 1134159429
$17,986.57
in general payments reported to CMS, 2019-2025
55 companies · $2,726 in 2025
The $2,726 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,594 · 2020: $1,323 · 2021: $2,775 · 2022: $2,280 · 2023: $3,307 · 2024: $2,982 · 2025: $2,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,966 · Long Term Medical Supply Or Device Loan: $39.96 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,966.14 |
| Long Term Medical Supply Or Device Loan | $39.96 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,920.52 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,811.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,730.56 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $1,395.97 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,276.45 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $905.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $836.56 | 2019-2025 | Jardiance |
| Abbvie INC. | $830.55 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Teva Pharmaceuticals USA, INC. | $595.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $594.99 | 2019-2025 | Arexvy, Penmenvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $465.71 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $380.92 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Abbott Laboratories | $365.13 | 2022-2024 | Freestyle Libre 3, Diamondback Peripheral, Freestyle Insulinx |
| Sanofi-Aventis U.S. LLC | $330.03 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.85 | 2023-2024 | Xifaxan |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $230.76 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $213.92 | 2022-2023 | Quviviq |
| Amgen INC. | $210.87 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Alexion Pharmaceuticals, INC. | $203.21 | 2019 | |
| Intra-Sana Laboratories | $183.89 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Aimmune Therapeutics, INC. | $181.01 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $170.87 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $154.59 | 2019 | |
| Medtronic Vascular, INC. | $132.26 | 2019 | |
| Cook Medical LLC | $125.69 | 2023 | Zilver Ptx |
| Medtronic, INC. | $123.75 | 2022-2023 | Reveal Linq, Intellis Adaptivestim |
| Regeneron Healthcare Solutions, INC. | $122.73 | 2023 | Dupixent |
| Dexcom, INC. | $118.88 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $94.16 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $91.24 | 2019-2025 | Rexulti |
| Mayne Pharma Commercial LLC | $76.64 | 2023-2025 | |
| Cranial Technologies, INC | $74.26 | 2020-2024 | Doc Band |
| Biohaven Pharmaceutical Holding Company LTD. | $72.09 | 2022 | |
| Allergan, INC. | $72.03 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $71.71 | 2024-2025 | |
| Phadia US INC. | $60.18 | 2023-2024 | Immunocap |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.15 | 2025 | Caplyta |
| Hologic Sales and Service, LLC | $49.12 | 2019-2021 | |
| Electromed, INC. | $44.84 | 2025 | Smartvest |
| Phathom Pharmaceuticals, INC. | $34.32 | 2024-2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $32.51 | 2021-2024 | Givlaari |
| Xeris Pharmaceuticals, INC. | $29.54 | 2024 | Gvoke Hypopen |
| Antares Pharma, INC. | $26.39 | 2024 | Xyosted |
| Philips North America LLC | $24.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.99 | 2024 | Eliquis |
| Genzyme Corporation | $20.71 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $20.20 | 2025 | Zoryve |
| Forte Bio-Pharma LLC | $19.74 | 2020 | |
| Averitas Pharma INC. | $19.51 | 2024 | Qutenza |
| Genentech USA, INC. | $19.01 | 2020 | |
| Gilead Sciences, INC. | $16.05 | 2021 | |
| Lnhc, INC | $14.32 | 2025 | Zelsuvmi |
| Grt US Holding, INC. | $13.98 | 2022 | |
| Mannkind Corporation | $11.91 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $11.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Concepcion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.